This is an active research project. This project has been identified and qualified by GSLI’s qualification standards. Though the company is conducting site selection on their own, our goal is to present new opportunities and create awareness for locations not in the original scope of consideration. If you are interested in a submission, please submit based on what information we have and we will attempt to introduce your area to the project for 2-3 weeks after the submission deadline has passed. If we do not hear back from the project 2-3 weeks after the submission deadline, we will release the contact information for your own personal outreach.
The company is looking for a greenfield site to construct a new 40,000 sq ft facility. Currently, they are interested in the Great Lakes, North East, and New England Regions of the U.S. They are interested in reviewing both lease/purchase opportunities at this time. At the facility, the company will focus on manufacturing viral vectors, which are used to create vaccines and are used in cell and gene therapy. They expect to create 65 jobs by year 2 at the facility, which will be high-paying positions.
States of Interest
Connecticut, Illinois, Indiana, Maine, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Vermont, Wisconsin
Regions of Interest
Great Lakes, New England, Northeast
2-5 acres of greenfield land.
-Ample space for employee parking and visitors.
-Does not need access to rail or port.
-Wants to be near other biohealth companies.
-Densely populated area.
-Close proximity to Colleges/Universities is a plus.
-Access to utilities (e.g., electricity, sewer, water, phone)
Qualification Date: 29 Nov 2021
Decision Time Frame: 6 to 12 Months
Submit Before: December 23, 2021 05:00 PM
Initial RFI Submission: December 23, 2021 05:00 PM
Globally known full-service contract research organization with a focused curative approach that provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise. The company sees major challenges that could delay medical advancements due to the manufacturing shortage in the industry, which is why they have decided to enter the manufacturing arena. The company has over 20 years of experience and conducts business on more than 5 continents.